This study is testing a new treatment called Mirvetuximab Soravtansine for women with certain types of cancer: ovarian, fallopian tube, or peritoneal. These cancers are platinum-sensitive, meaning they respond well to a type of chemotherapy. The study compares the new treatment with another called Bevacizumab, which is already used. Mirvetuximab Soravtansine is a special medicine that targets cancer cells with high amounts of a protein called folate receptor-alpha (FRα). If you join, doctors will check if your cancer has this protein. To join, you must be over 18, have had some specific treatments before, and meet other health requirements.

• Study duration and number of visits: Participants will receive treatment until the disease progresses or they experience unacceptable side effects.
• Compensation: Participants may receive reimbursement for travel or other study-related expenses.
• Risks: Possible side effects may include fatigue, nausea, and low blood counts.

It's important to discuss participation with your doctor to understand all potential risks and benefits. You must agree to use birth control during the study if you're capable of having children, and you can't join if you're pregnant or breastfeeding.